Morgan Stanley analyst Andrew Galler maintains Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Equal-Weight and lowers the price target from $41 to $37.
Trian Fund Management, L.P. (together with its affiliates, "Trian" or "we") beneficially owns approximately $3 billion of stock in The Walt Disney Company (NYSE:DIS) ("Disney" or the "Company"). This morning, following